ORIC Pharmaceuticals, Inc.
ORICNASDAQHealthcareBiotechnology
Previous close
$14.20
+$0.32 · +2.31%
ORIC company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
35
Expensive
Momentum
52
Neutral
Sentiment
58
Mixed
Risk resilience
46
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Jacob Chacko
- Listed since
- Apr 24, 2020
- Employees
- 111
Market position
Day range
Current $14.20
52-week range
Current $14.20
- Open
- $13.805
- Previous close
- $13.88
- Volume
- 970.49K
- 0.6× average
- Average volume
- 1.61M
- Average daily volume
- Market cap
- 1.47B USD
- Beta
- 0.97
- Market reference 1
- 50-day average
- $11.2569
- +26.14% above average
- 200-day average
- $10.6164
- +33.76% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 684.04M USD
- P/E (TTM)
- -10.52×
- P/B (TTM)
- 4.02×
- P/S (TTM)
- 0×
- EV / EBITDA
- -5.33×
- Earnings yield
- -18.03%
- Free cash flow yield
- -15.89%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -33.68%
- Return on assets
- -31.50%
- Return on invested capital
- -36.30%
Financial health
- Debt / equity
- 0.01×
- Current ratio
- 14.13×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 1.22M USD | 1.11M USD | 1.03M USD | — | — |
| Gross profit | −1.22M USD | −1.11M USD | −1.03M USD | — | — |
| Research and development | 109.82M USD | 114.07M USD | 85.17M USD | 61.68M USD | 56.86M USD |
| Selling, general, and administrative | 33.19M USD | 28.82M USD | 25.61M USD | 25.09M USD | 22.01M USD |
| Operating expenses | 141.78M USD | 141.79M USD | 109.75M USD | 91.77M USD | 78.87M USD |
| Interest income | — | — | 10.08M USD | 2.65M USD | 141K USD |
| Interest expense | — | — | — | 2.65M USD | — |
| Depreciation and amortization | 1.22M USD | 1.11M USD | 1.03M USD | 966K USD | 897K USD |
| Operating income | −143M USD | −142.9M USD | −110.78M USD | −91.77M USD | −78.87M USD |
| Net income | −129.47M USD | −127.85M USD | −100.7M USD | −89.12M USD | −78.72M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 45%
- 5 beats, 5 misses, 1 met estimate
- Average EPS surprise
- +3.96%
- 11 comparable reports
- Latest EPS result
- -0.38
- Estimate -0.36 · Miss by 5.75%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$19.00
33.80% upsideRating distribution
10 ratingsRecent analyst actions
ORIC news
ORIC peers
ETFs holding ORIC
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI47.57M0.42%11.39B USD0.35%$165.73+1.44%
Vanguard Morningstar Total Stock Market ETFVTI32.79M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 ETFIWM26.61M0.03%81.62B USD0.19%$299.96+0.77%
Vanguard Extended Market ETFVXF10.45M0.01%93.7B USD0.05%$245.53+0.82%
iShares Russell 2000 Value ETFIWN6.66M0.05%14.66B USD0.24%$224.81+0.45%
iShares Biotechnology ETFIBB6.41M0.06%10.75B USD0.44%$213.56+1.29%
Schwab U.S. Small-Cap ETFSCHA5.39M0.02%23.1B USD0.03%$34.83+0.52%
Vanguard Russell 2000 ETFVTWO4.64M0.03%17.4B USD0.06%$121.25+0.74%State Street SPDR S&P Biotech ETFXBI- Market value
- 47.57M
- Weight
- 0.42%
- AUM
- 11.39B USD
- Expense ratio
- 0.35%
- Price / 1D
- $165.73+1.44%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 32.79M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 ETFIWM- Market value
- 26.61M
- Weight
- 0.03%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Extended Market ETFVXF- Market value
- 10.45M
- Weight
- 0.01%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Russell 2000 Value ETFIWN- Market value
- 6.66M
- Weight
- 0.05%
- AUM
- 14.66B USD
- Expense ratio
- 0.24%
- Price / 1D
- $224.81+0.45%
iShares Biotechnology ETFIBB- Market value
- 6.41M
- Weight
- 0.06%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
Schwab U.S. Small-Cap ETFSCHA- Market value
- 5.39M
- Weight
- 0.02%
- AUM
- 23.1B USD
- Expense ratio
- 0.03%
- Price / 1D
- $34.83+0.52%
Vanguard Russell 2000 ETFVTWO- Market value
- 4.64M
- Weight
- 0.03%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
Continue in GoAI
Research ORICresearch.disclaimer